Caption
Fig. 1. Illustration of the drug imatinib (brand name Gleevec®, shown in green) bound in a deep cavitiy of the tyrosine-kinase ABL2. By its binding mode, the drug is able to inhibit the protein and is therefore being used for the treatment of chronic myeloid leukemia.